Literature DB >> 15322741

Significance of Bio-intact PTH(1-84) assay in hemodialysis patients.

Masaaki Inaba1, Senji Okuno, Yasuo Imanishi, Misako Ueda, Tomoyuki Yamakawa, Eiji Ishimura, Yoshiki Nishizawa.   

Abstract

The aim of the present study was to examine whether the newly developed bio-intact parathyroid hormone (Bio-PTH) assay, which exclusively measures the intact PTH(1-84) molecule, provides a better assay for estimating parathyroid function in hemodialysis (HD) patients, and to evaluate the factors associated with serum PTH levels measured by Bio-PTH assay and by second-generation intact PTH (I-PTH) assay. The study also examined whether Bio-PTH/I-PTH ratio, an index of the active fraction of PTH, could provide information not obtainable from simple PTH results. Serum levels of PTH were measured in 177 male HD patients, together with the bone formation markers bone alkaline phosphatase (BAP), intact osteocalcin (iOC), N-midfragment osteocalcin (N-Mid OC), and N-terminal propeptide of type I collagen (PINP), and the bone resorption markers deoxypyridinoline (DPD), pyridinoline (PYD), and beta-CrossLaps (beta-CTx). Bone mineral density (BMD) was determined twice at distal radius one-third by dual-energy X-ray absorptiometry. Serum Bio-PTH was significantly elevated in HD patients compared to normal controls. Serum Bio-PTH and I-PTH correlated significantly in a positive manner with serum bone formation markers (BAP, iOC, N-Mid OC, PINP), and resorption markers (DPD, PYD, beta-CTx), and in a negative manner with BMD and annual change therein at distal radius one-third. The degree of correlation of Bio-PTH was not significantly different from that of I-PTH. The Bio-PTH/I-PTH ratio was significantly lower in HD patients than in normal individuals, due probably to accumulation of N-truncated PTH fragments in the former. The Bio-PTH/I-PTH ratio correlated significantly in a negative manner with serum calcium (Ca) (r=-0.251, P<0.001) and nutritional marker serum urea nitrogen, protein catabolic rate and serum creatinine. Multiple regression analysis further revealed that serum I-PTH, but not Bio-PTH, was significantly associated with each of these nutritional markers, and that the Bio-PTH/I-PTH ratio was negatively associated with serum Ca. It was also found that I-PTH, but not Bio-PTH, was influenced by nutritional state. It is concluded that serum Bio-PTH assay could be of similar value to I-PTH assay in evaluating parathyroid function in HD patients and that their combined use in the form of the Bio-PTH/I-PTH ratio could provide information not obtainable from simple PTH results.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15322741     DOI: 10.1007/s00198-004-1715-1

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  33 in total

1.  Technical and clinical characterization of the Bio-PTH (1-84) immunochemiluminometric assay and comparison with a second-generation assay for parathyroid hormone.

Authors:  Masaaki Inaba; Kiyoshi Nakatsuka; Yasuo Imanishi; Masakazu Watanabe; Yuji Mamiya; Eiji Ishimura; Yoshiki Nishizawa
Journal:  Clin Chem       Date:  2003-12-18       Impact factor: 8.327

2.  Hyperparathyroidism is augmented by ovariectomy in Nagase analbuminemic rats.

Authors:  M Inaba; H Morii; T Katsumata; H Goto; E Ishimura; T Kawagishi; M Kamao; T Okano; Y Nishizawa
Journal:  J Nutr       Date:  2000-06       Impact factor: 4.798

3.  Effects of plasma calcium concentration on the relative proportion of hormone and carboxyl fragments in parathyroid venous blood.

Authors:  G P Mayer; J A Keaton; J G Hurst; J F Habener
Journal:  Endocrinology       Date:  1979-06       Impact factor: 4.736

4.  Protective effect of an aldose reductase inhibitor against bone loss in galactose-fed rats: possible involvement of the polyol pathway in bone metabolism.

Authors:  M Inaba; M Terada; Y Nishizawa; A Shioi; E Ishimura; S Otani; H Morii
Journal:  Metabolism       Date:  1999-07       Impact factor: 8.694

5.  A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: implications for PTH measurements in renal failure.

Authors:  M R John; W G Goodman; P Gao; T L Cantor; I B Salusky; H Jüppner
Journal:  J Clin Endocrinol Metab       Date:  1999-11       Impact factor: 5.958

6.  Increasing body fat mass in the first year of hemodialysis.

Authors:  Eiji Ishimura; Senji Okuno; Masao Kim; Tadashi Yamamoto; Tsuyoshi Izumotani; Tatsuyuki Otoshi; Tetsuo Shoji; Masaaki Inaba; Yoshiki Nishizawa
Journal:  J Am Soc Nephrol       Date:  2001-09       Impact factor: 10.121

7.  PTH 1-84 and PTH "7-84" in the noninvasive diagnosis of renal bone disease.

Authors:  Giorgio Coen; Ermanno Bonucci; Paola Ballanti; Alessandro Balducci; Santo Calabria; Giulia A Nicolai; Maria Stephanie Fischer; Francesca Lifrieri; Micaela Manni; Massimo Morosetti; Eleonora Moscaritolo; Daniela Sardella
Journal:  Am J Kidney Dis       Date:  2002-08       Impact factor: 8.860

8.  Clinical usefulness of the serum N-terminal propeptide of type I collagen as a marker of bone formation in hemodialysis patients.

Authors:  Misako Ueda; Masaaki Inaba; Senji Okuno; Kyoko Nagasue; Kayoko Kitatani; Eiji Ishimura; Motokazu Shimizu; Takami Miki; Masao Kim; Yoshiki Nishizawa
Journal:  Am J Kidney Dis       Date:  2002-10       Impact factor: 8.860

9.  Origin of parathyroid hormone (PTH) fragments detected by intact-PTH assays.

Authors:  L Nguyen-Yamamoto; L Rousseau; J-H Brossard; R Lepage; P Gao; T Cantor; P D'Amour
Journal:  Eur J Endocrinol       Date:  2002-07       Impact factor: 6.664

10.  Administration of PTH-(7-84) antagonizes the effects of PTH-(1-84) on bone in rats with moderate renal failure.

Authors:  M Chris Langub; Marie-Claude Monier-Faugere; Guodong Wang; John P Williams; Nicholas J Koszewski; Hartmut H Malluche
Journal:  Endocrinology       Date:  2003-04       Impact factor: 4.736

View more
  7 in total

1.  Association of increased active PTH(1-84) fraction with decreased GFR and serum Ca in predialysis CRF patients: modulation by serum 25-OH-D.

Authors:  M Kurajoh; M Inaba; S Yamada; Y Imanishi; T Tsuchida; E Ishimura; Y Nishizawa
Journal:  Osteoporos Int       Date:  2008-02-01       Impact factor: 4.507

2.  Increased active PTH(1-84) fraction as a predictor of poor mortality in male hemodialysis patients.

Authors:  M Inaba; S Okuno; Y Imanishi; E Ishimura; T Yamakawa; S Shoji
Journal:  Osteoporos Int       Date:  2013-09-13       Impact factor: 4.507

Review 3.  Lessons from a second- and third-generation parathyroid hormone assays in renal failure patients.

Authors:  P D'Amour
Journal:  J Endocrinol Invest       Date:  2008-05       Impact factor: 4.256

4.  Reduction of whole PTH/intact PTH ratio as a predictor of bone metabolism in cinacalcet treatment of hemodialysis patients with secondary hyperparathyroidism.

Authors:  M Kurajoh; M Inaba; S Okuno; H Nagayama; S Yamada; Y Imanishi; E Ishimura; S Shoji; T Yamakawa; Y Nishizawa
Journal:  Osteoporos Int       Date:  2010-05-07       Impact factor: 4.507

5.  Role of fibroblast growth factor-23 in peripheral vascular calcification in non-diabetic and diabetic hemodialysis patients.

Authors:  M Inaba; S Okuno; Y Imanishi; S Yamada; A Shioi; T Yamakawa; E Ishimura; Y Nishizawa
Journal:  Osteoporos Int       Date:  2006-08-05       Impact factor: 4.507

6.  Decreased cortical thickness, as estimated by a newly developed ultrasound device, as a risk for vertebral fracture in type 2 diabetes mellitus patients with eGFR of less than 60 mL/min/1.73 m2.

Authors:  T Mishima; K Motoyama; Y Imanishi; K Hamamoto; Y Nagata; S Yamada; N Kuriyama; Y Watanabe; M Emoto; M Inaba
Journal:  Osteoporos Int       Date:  2014-09-04       Impact factor: 4.507

7.  Significance of urinary C-megalin excretion in vitamin D metabolism in pre-dialysis CKD patients.

Authors:  Norikazu Toi; Masaaki Inaba; Eiji Ishimura; Naoko Tsugawa; Yasuo Imanishi; Masanori Emoto; Yoshiaki Hirayama; Shinya Nakatani; Akihiko Saito; Shinsuke Yamada
Journal:  Sci Rep       Date:  2019-02-18       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.